Literature DB >> 12057868

Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.

Daniel Brattström1, M Bergqvist, P Hesselius, A Larsson, K Lamberg, J Wernlund, O Brodin, G Wagenius.   

Abstract

We have analysed the predictive and prognostic information in preoperatively collected serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients clinically evaluated as operable non-small cell lung cancer (NSCLC). Fifty-eight patients with operable NSCLC were included. VEGF and bFGF levels in serum were analysed using enzyme linked immunosorbent assays (Quantikine human VEGF and Quantikine HS human FGF basic, R&D Systems). Univariate analysis demonstrated that tumour volume, platelet counts, VEGF and bFGF were significant prognostic factors. However, only bFGF remained significant in the multivariate analysis (P=0.014). Significant correlation's were demonstrated between VEGF levels and tumour volume (r=0.33; P=0.012) and platelet count (r=0.43; P=0.001). bFGF levels correlated significant with recurrent disease (r=0.34; P=0.01), platelet count (r=0.53, P<0.001) and performance status (r=0.29; P=0.029). Furthermore, bFGF levels and VEGF levels correlated significantly (r=0.44; P<0.001). We conclude that elevated circulating angiogenic cytokines correlate with tumour volume, higher relapse risk and poorer survival in patients with operable non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057868     DOI: 10.1016/s0169-5002(02)00027-2

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  17 in total

1.  The clinical significance of vascular endothelial growth factor in malignant ascites.

Authors:  Na Zhan; Wei-Guo Dong; Jing Wang
Journal:  Tumour Biol       Date:  2015-10-13

2.  Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

Authors:  Martin J Edelman; Lydia Hodgson; Xiaofei Wang; Robert Christenson; Scott Jewell; Everett Vokes; Robert Kratzke
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

3.  Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course.

Authors:  Jin-Hai Tang; Jian-Hua Zhao; Jian-Wei Lu; Feng Yan; Jian-Wei Qin; Bin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-10       Impact factor: 4.553

4.  The role of cystatin C and the angiogenic cytokines VEGF and bFGF in patients with esophageal carcinoma.

Authors:  Martin Dreilich; Gunnar Wagenius; Stefan Bergström; Daniel Brattström; Anders Larsson; Patrik Hesselius; Michael Bergqvist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 5.  Targeting angiogenesis in squamous non-small cell lung cancer.

Authors:  Bilal Piperdi; Amartej Merla; Roman Perez-Soler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

6.  Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.

Authors:  Håkan Garpenstrand; Michael Bergqvist; Daniel Brattström; Anders Larsson; Lars Oreland; Patrik Hesselius; Gunnar Wagenius
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer.

Authors:  C Bodelon; M Y Polley; T J Kemp; A C Pesatori; L M McShane; N E Caporaso; A Hildesheim; L A Pinto; M T Landi
Journal:  Ann Oncol       Date:  2013-05-16       Impact factor: 32.976

8.  High circulating VEGF level predicts poor overall survival in lung cancer.

Authors:  Pingping Hu; Weidong Liu; Liguang Wang; Miaomiao Yang; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-04       Impact factor: 4.553

Review 9.  The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Scott A Kono; Marianne E Marshall; Kathryn E Ware; Lynn E Heasley
Journal:  Drug Resist Updat       Date:  2009-06-04       Impact factor: 18.500

10.  Growth factor mediated signaling in pancreatic pathogenesis.

Authors:  Debashis Nandy; Debabrata Mukhopadhyay
Journal:  Cancers (Basel)       Date:  2011-02-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.